a From Hemomed - Instituto de Oncologia e Hematologia & IEP Sao Lucas, Sao Paulo, and the Gastrointestinal Cancer Unit, Medical Oncology Department and Radiology Department, Hospital de Câncer de Barretos, Barretos, Brazil.
Imatinib mesylate represents a revolution in the management of patients with metastatic gastrointestinal stromal tumors (GISTs). More recently, postoperative imatinib has been shown to improve both disease-free and overall survivals in patients with a high risk of recurrence. This article presents a well-documented case of a patient with painful and reversible bone edema related to imatinib.
Correspondence: Lucas Vieira dos Santos, MD, Hemomed - Instituto de Oncologia e Hematologia & IEP Sao Lucas, 121 Arnolfo de Azevedo Ave, Sao Paulo, Brazil 01236-030. E-mail: email@example.com